Stoke Therapeutics (NASDAQ:STOK) Insider Sells $203,473.64 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 6,164 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $33.01, for a total transaction of $203,473.64. Following the completion of the transaction, the insider directly owned 47,484 shares in the company, valued at approximately $1,567,446.84. The trade was a 11.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.99, for a total transaction of $43,815.39.

Stoke Therapeutics Trading Up 1.0%

STOK stock opened at $33.51 on Friday. The firm’s 50-day moving average price is $32.61 and its two-hundred day moving average price is $30.09. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $40.22. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of 50.01 and a beta of 1.07.

Analyst Ratings Changes

A number of research analysts have commented on STOK shares. Needham & Company LLC upped their price target on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research note on Thursday. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Loop Capital set a $35.00 price target on Stoke Therapeutics in a research note on Monday, January 5th. Finally, UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of STOK. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the 4th quarter valued at approximately $26,000. Harbour Investments Inc. grew its holdings in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the period. Generali Investments Management Co LLC bought a new position in shares of Stoke Therapeutics in the 3rd quarter worth approximately $41,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.